A Study of LY2409021 Formulations and the Effect of Food

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are to compare how much of LY2409021 enters the bloodstream and how long the body takes to get rid of the drug when different formulations of LY2409021 are given, and when LY2409021 is taken with or without food. The study will be conducted in 2 cohorts. Each cohort will have 3 study periods consisting of 3 formulations of LY2409021. Participants in each cohort will receive the same all 3 formulations using a randomized sequence crossover design. There is a washout period of at least 14 days between dosing periods. There will be an interim analysis after Cohort 1 completes study Period 2. Cohort 2 will not begin enrolling until this analysis is complete. The need to enroll Cohort 2 will be determined by the outcome of the interim analysis.

Official Title
-----------------
LY2409021 Formulation Bridging and Food Effect Study

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: LY2409021 Reference Form
* Drug: LY2409021 Test-Med Formulation (medium particle size)
* Drug: LY2409021 Test-High Formulation (high particle size)
* Drug: LY2409021 Test-Low Formulation (low particle size)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be healthy male or a healthy female who cannot become pregnant Must have body mass index (BMI) of 18.5 to 32 kilograms per meter squared (kg/m²), inclusive Blood pressure as well as blood and urine laboratory test results must be acceptable for the study The veins must be suitable for easy blood collection Must be willing to be available for the whole study and be willing to follow study procedures Exclusion Criteria: Were in another new drug or medical research study in the last 30 days Have previously taken part in this study or any other study with LY2409021 Have taken LY2409021, or drugs similar to LY2409021 before and was found to be allergic to the drug Currently have or used to have health problems or laboratory test results that in the opinion of the doctor, could interfere with understanding the results of this study Electrocardiogram (ECG) readings are not suitable for the study Are infected with hepatitis B Are infected with human immunodeficiency disease virus (HIV) Are using or intend to use over-the-counter medication or prescription medications within 14 days, from the start of the first study dosing until end of study Have a regular alcohol intake greater than 21 units per week (males) and 14 units per week (females) or are not willing to abstain from alcohol while in the research unit Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while at the clinic Have a history of drug or alcohol abuse Have donated 450 milliliters (mL) or more of blood in the last 3 months Are unwilling or unable to comply with dietary requirements/restrictions during the study The study doctor thinks the participant should not participate for any other reasons

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1 - LY2409021 reference form<br>A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state | Drug: LY2409021 Reference Form<br>* Administered orally<br>|
| Experimental: Cohort 1 - LY2409021 medium test form fed<br>Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal | Drug: LY2409021 Test-Med Formulation (medium particle size)<br>* Administered orally<br>|
| Experimental: Cohort 1 - LY2409021 medium test form fasted<br>Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state | Drug: LY2409021 Test-Med Formulation (medium particle size)<br>* Administered orally<br>|
| Experimental: Cohort 2 - LY2409021 low test form fasted<br>Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state | Drug: LY2409021 Test-Low Formulation (low particle size)<br>* Administered orally<br>|
| Experimental: Cohort 2 - LY2409021 medium test form fasted<br>Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state | Drug: LY2409021 Test-Med Formulation (medium particle size)<br>* Administered orally<br>|
| Experimental: Cohort 2 - LY2409021 high test form fasted<br>Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state | Drug: LY2409021 Test-High Formulation (high particle size)<br>* Administered orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Medium Test Form to Reference Form | AUC from time 0 to infinity (AUC0-∞). | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 
| Pharmacokinetics, Maximum Concentration (Cmax): Medium Test Form to Reference Form |  | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Standardized High Fat Meal to Fasting | AUC from time 0 to infinity (AUC0-∞). | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 
| Pharmacokinetics, Maximum Concentration (Cmax): Standardized High Fat Meal to Fasting |  | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 
| Pharmacokinetics, Time to Maximum Concentration (Tmax) |  | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 
| Pharmacokinetics, Area Under the Concentration-Time Curve (AUC): Low and High Particle Size to Medium Particle Size | AUC from time 0 to infinity (AUC0-∞). | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 
| Pharmacokinetics, Concentration Maximum (Cmax): Low and High Particle Size to Medium Particle Size |  | Periods 1, 2, 3 (predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 144, 192, 240, 288, and 336 hours postdose) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy Volunteers, Bioavailability